Richard J. Beninger

Richard J. Beninger

Auto-generated profile, based on publicly available information

Richard J. Beninger

Queen’s University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
HSHenry Szechtman
Henry Szechtman
SASusanne E. Ahmari
Susanne E. Ahmari
RBRichard J. Beninger
Richard J. Beninger
DEDavid Eilam
David Eilam
BHBrian Herbert Harvey
Brian Herbert Harvey
CWChristine Winter
Christine Winter

1 March 2008 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
RBRichard J. Beninger
Richard J. Beninger
TBTomek J. Banasikowski
Tomek J. Banasikowski

18 November 2011 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
TBTomek J. Banasikowski
Tomek J. Banasikowski
RBRichard J. Beninger
Richard J. Beninger
Decreases in brain dopamine (DA) lead to catalepsy, quantified by the time a rat remains with its forepaws resting on a suspended horizontal bar. Low

1 September 2009 in Behavioural Brain Research
Verified
Journal Article
Closed access
RBRichard J. Beninger
Richard J. Beninger
KTKatharine J. Tuerke
Katharine J. Tuerke
JFJennifer K. Forsyth
Jennifer K. Forsyth
AGAndrew Giles
Andrew Giles
LXLihua Xue
Lihua Xue
KJKhem Jhamandas
Khem Jhamandas

1 February 2009 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
RBRichard J. Beninger
Richard J. Beninger
JFJennifer K. Forsyth
Jennifer K. Forsyth
MAMichael Van Adel
Michael Van Adel
JRJames N. Reynolds
James N. Reynolds
RBRoland J. Boegman
Roland J. Boegman
KJKhem Jhamandas
Khem Jhamandas

1 February 2010 in Behavioural Pharmacology
Verified
Journal Article
Closed access
RBRichard J. Beninger
Richard J. Beninger
JBJonathan Beuk
Jonathan Beuk
TBTomek J. Banasikowski
Tomek J. Banasikowski
MAMichael van Adel
Michael van Adel
GBGregory A. Boivin
Gregory A. Boivin
JRJames N. Reynolds
James N. Reynolds
Phencyclidine (PCP), an antagonist at the N-methyl-D-aspartate subtype of ionotropic glutamatergic receptors, decreases gamma-aminobutyric acid (GABA)ergic inhibition, suggesting that changes in GABAergic receptor function underlie behavioral and cognitive deficits resulting from repeated administration of PCP. To test this hypothesis, male Sprague-Dawley rats treated with PCP (4.5 mg/kg, intraperitoneal, twice a day for 7 consecutive days) or saline were tested in behavioral and cognitive tasks 7 days after injections. The PCP group showed increased amphetamine (1.5 mg/kg)-stimulated locomotor activity, and exhibited a greater number of errors in the double Y-maze memory task, when compared with controls. Subchronic PCP treatment increased [H]muscimol-binding sites and decreased affinity for [H]muscimol binding in frontal cortex, hippocampus, and striatum in comparison with controls. There were no changes in the expression of glutamic acid decarboxylase or the GABA membrane transporter protein. These data show that subchronic PCP administration induces an impaired performance of a previously learned task and an enhanced response to amphetamine in the rat. The observed changes in GABAA receptors in the rat brain are consistent with the notion that alterations in GABAergic receptor function contribute to the behavioral and cognitive impairments associated with repeated exposure to PCP.